Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC 2.7.11.1) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC 2.7.11.1) – Pipeline Review, H2 2016’, provides in depth analysis on Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC 2.7.11.1) targeted pipeline therapeutics.

The report provides comprehensive information on the Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC 2.7.11.1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC 2.7.11.1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC 2.7.11.1)

The report reviews Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects

The report assesses Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC 2.7.11.1) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC 2.7.11.1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC 2.7.11.1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

AbbVie Inc

Advenchen Laboratories LLC

Aeterna Zentaris Inc

Amgen Inc

Astex Pharmaceuticals Inc

AstraZeneca Plc

Chipscreen Biosciences Ltd

Cielo Therapeutics Inc

Merck KGaA

Nemucore Medical Innovations Inc

Sanofi

Sareum Holdings Plc

Vertex Pharmaceuticals Inc

Vichem Chemie Research Ltd

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC

2.7.11.1) Overview 9

Therapeutics Development 10

Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC

2.7.11.1) - Products under Development by Stage of Development 10

Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC

2.7.11.1) - Products under Development by Therapy Area 11

Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC

2.7.11.1) - Products under Development by Indication 12

Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC

2.7.11.1) - Pipeline Products Glance 14

Late Stage Products 14

Early Stage Products 15

Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC

2.7.11.1) - Products under Development by Companies 16

Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC

2.7.11.1) - Products under Development by Universities/Institutes 20

Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC

2.7.11.1) - Therapeutics Assessment 22

Assessment by Monotherapy/Combination Products 22

Assessment by Mechanism of Action 23

Assessment by Route of Administration 24

Assessment by Molecule Type 26

Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC

2.7.11.1) - Companies Involved in Therapeutics Development 27

AbbVie Inc 27

Advenchen Laboratories LLC 28

Aeterna Zentaris Inc 29

Amgen Inc 30

Astex Pharmaceuticals Inc 31

AstraZeneca Plc 32

Chipscreen Biosciences Ltd 33

Cielo Therapeutics Inc 34

Merck KGaA 35

Nemucore Medical Innovations Inc 36

Sanofi 37

Sareum Holdings Plc 38

Vertex Pharmaceuticals Inc 39

Vichem Chemie Research Ltd 40

Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC

2.7.11.1) - Drug Profiles 41

AL-8326 - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

AMG-900 - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

AT-9283 - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

AZD-2811 - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

CS-2164 - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

danusertib - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

ilorasertib - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

NMI-900 - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

SAR-156497 - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

SAR-3 - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

SAR-4 - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

Small Molecule to Inhibit Aurora B Kinase for Pancreatic Cancer - Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

Small Molecules to Inhibit Aurora A/B Kinase for Oncology - Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

Small Molecules to Inhibit Aurora B Kinase for Oncology - Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

Small Molecules to Inhibit ERK2 and Aurora B Kinase for Oncology - Drug Profile 61

Product Description 61

Mechanism Of Action 61

R&D Progress 61

VE-465 - Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC

2.7.11.1) - Dormant Projects 63

Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC

2.7.11.1) - Discontinued Products 70

Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC

2.7.11.1) - Featured News & Press Releases 72

Aug 03, 2016: China and Hong Kong Patent Grants for Sareum’s Aurora+FLT3 Kinase Inhibitors 72

May 10, 2016: Data Published in Journal of Controlled Release Demonstrate Flexibility of ACCURINS to Encapsulate a Broad Range of Physically and Chemically Diverse Payloads with High Encapsulation Efficiency and Tunable Release Kinetics 72

Feb 10, 2016: AZD2811 ACCURINS Data Published in Science Translational Medicine Highlight One of the First Applications of Nanomedicine to Molecularly Targeted Cancer Therapies 73

Nov 18, 2015: BIND Therapeutics Announces Initiation of Clinical Studies with Accurin AZD2811 in Solid Tumors 74

Sep 15, 2015: US and European Patent Grants for Sareum's Aurora+FLT3 Kinase Inhibitors 75

Jun 23, 2015: BIND Therapeutics Announces FDA Authorization of First-in-Human Clinical Trial with AstraZeneca's Aurora B Kinase Inhibitor Accurin AZD2811 76

Apr 22, 2015: BIND Therapeutics Presents Data Highlighting Ability of Accurin drug candidate AZD2811 to Accumulate in Target Tissue at AACR Annual Meeting 2015 77

Mar 18, 2015: Data from Abstracts Validating Potential of BIND Therapeutics AZD2811 to be Presented at American Association for Cancer Research Annual Meeting 78

Mar 05, 2014: BIND Therapeutics to Present Data on Barasertib at the AACR 2014 Annual Meeting 79

Jul 15, 2013: Preclinical Development Candidate Selected for Aurora+FLT3 Inhibitor Programme 79

Sep 03, 2012: Chipscreen filed a new IND application on a novel dual-pathway targeted inhibitor Chiauranib to SFDA 79

May 16, 2012: Astex Pharmaceuticals To Present Data On AT9283 At ASCO Annual Meeting 80

Jan 27, 2012: Cancer Research UK Launches Trial Of New Drug To Treat Acute Childhood Leukemia 80

Dec 01, 2010: Astex to Present Encouraging Data on AT9283 in Combination with Docetaxel for Treatment of Non-Hodgkin’s Lymphoma 81

Dec 01, 2010: Astex To Present Encouraging Data On AT9283 In Combination With Lenalidomide For Treatment Of Multiple Myeloma At ASH Annual Meeting 81

Appendix 82

Methodology 82

Coverage 82

Secondary Research 82

Primary Research 82

Expert Panel Validation 82

Contact Us 82

Disclaimer 83

List of Tables

List of Tables

Number of Products under Development for, H2 2016 10

Number of Products under Development by Therapy Area, H2 2016 11

Number of Products under Development by Indication, H2 2016 13

Comparative Analysis by Late Stage Development, H2 2016 14

Comparative Analysis by Early Stage Products, H2 2016 15

Number of Products under Development by Companies, H2 2016 16

Products under Development by Companies, H2 2016 17

Products under Development by Companies, H2 2016 (Contd..1) 18

Products under Development by Companies, H2 2016 (Contd..2) 19

Number of Products under Investigation by Universities/Institutes, H2 2016 20

Products under Investigation by Universities/Institutes, H2 2016 21

Assessment by Monotherapy/Combination Products, H2 2016 22

Number of Products by Stage and Mechanism of Action, H2 2016 23

Number of Products by Stage and Route of Administration, H2 2016 25

Number of Products by Stage and Molecule Type, H2 2016 26

Pipeline by AbbVie Inc, H2 2016 27

Pipeline by Advenchen Laboratories LLC, H2 2016 28

Pipeline by Aeterna Zentaris Inc, H2 2016 29

Pipeline by Amgen Inc, H2 2016 30

Pipeline by Astex Pharmaceuticals Inc, H2 2016 31

Pipeline by AstraZeneca Plc, H2 2016 32

Pipeline by Chipscreen Biosciences Ltd, H2 2016 33

Pipeline by Cielo Therapeutics Inc, H2 2016 34

Pipeline by Merck KGaA, H2 2016 35

Pipeline by Nemucore Medical Innovations Inc, H2 2016 36

Pipeline by Sanofi, H2 2016 37

Pipeline by Sareum Holdings Plc, H2 2016 38

Pipeline by Vertex Pharmaceuticals Inc, H2 2016 39

Pipeline by Vichem Chemie Research Ltd, H2 2016 40

Dormant Projects, H2 2016 63

Dormant Projects (Contd..1), H2 2016 64

Dormant Projects (Contd..2), H2 2016 65

Dormant Projects (Contd..3), H2 2016 66

Dormant Projects (Contd..4), H2 2016 67

Dormant Projects (Contd..5), H2 2016 68

Dormant Projects (Contd..6), H2 2016 69

Discontinued Products, H2 2016 70

Discontinued Products (Contd..1), H2 2016 71

List of Figures

List of Figures

Number of Products under Development for, H2 2016 10

Number of Products under Development by Top 10 Indication, H2 2016 12

Comparative Analysis by Early Stage Products, H2 2016 15

Assessment by Monotherapy/Combination Products, H2 2016 22

Number of Products by Stage and Mechanism of Actions, H2 2016 23

Number of Products by Routes of Administration, H2 2016 24

Number of Products by Stage and Routes of Administration, H2 2016 24

Number of Products by Stage and Molecule Type, H2 2016 26

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports